Advertisement

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer

  • Beatriz Wills
  • Julie R. Brahmer
  • Jarushka Naidoo
Lung Cancer (HA Wakelee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lung Cancer

Opinion statement

Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospective clinical trial exists to guide recommendations for optimal and more specific immunosuppressive treatments rather than corticosteroids, further studies may lead to a more mechanistic-based approach towards these toxicities in the future. In relation to current practice, we recommend adherence to the recent published guidelines which emphasize the importance of early recognition and administration of temporary immunosuppressive therapy with corticosteroids in most cases, depending on the organ system involved, and the severity of toxicity. Recognition of these toxicities is increasingly important as the use of these agents expand within different indications for patients with lung cancers, and to other tumor types.

Keywords

Lung cancer Immune checkpoint inhibition Side effect Anti-PD-1 Anti-PD-L1 

Notes

Compliance with Ethical Standards

Conflict of Interest

Beatriz Wills declares that she has no conflict of interest.

Julie R. Brahmer has received research support through grants from Bristol-Myers Squibb, MedImmune/AstraZeneca, and Merck; has received compensation from Celgene, Merck, and Lilly for service as a consultant; has received compensation from Merck, Genentech, and Syndax for participation on advisory boards; and has served on advisory boards and as a consultant for Bristol-Myers Squibb but received no compensation.

Jarushka Naidoo has received research support through grants from Merck and MedImmune/AstraZeneca and has received compensation from Bristol-Myers Squibb and Takeda for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance.

  1. 1.
    GLOBOCAN 2012 v1.0: cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon: International Agency for Research on Cancer, 2013 (http://globocan.iarc.fr.ezp.welch.jhmi.edu).
  2. 2.
    Schwartz A, Cote M. Epidemiology of lung cancer. In: Ahmad A, Gadgeel SM, editors. Lung cancer and personalized medicine: current knowledge and therapies. New York: Springer; 2016. p. 21–41.CrossRefGoogle Scholar
  3. 3.
    Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    • Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. Checkmate 017: randomized, open-label, international phase 3 study that showed that overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel patients with advanced, previously treated squamous-cell NSCLC.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRefPubMedGoogle Scholar
  6. 6.
    • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50. KEYNOTE-010: phase 2/3 study that showed that pembrolizumab prolongs overall survival and has a favorable benefit t-to-risk profile in patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.CrossRefPubMedGoogle Scholar
  7. 7.
    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.CrossRefPubMedGoogle Scholar
  8. 8.
    • Rittmeyer A, Barlesi F, Waterkamp, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. OAK phase 3 study that showed that atezolizumab resulted in clinically significant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology.CrossRefPubMedGoogle Scholar
  9. 9.
    • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. PACIFIC: Phase 3 study that showed that progression-free survival was significantly longer with durvalumab than with placebo in patients with h locally advanced, unresectable, non-small-cell lung cancer (NSCLC).CrossRefPubMedGoogle Scholar
  10. 10.
    Hellmann M, Ramalingam S, Reck M, O'Byrne K, Paz-Ares L, Harbison CT, et al. An open label randomized phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC)(CheckMate 227). J Immunother Cancer. 2015;3(2):P154.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    • Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104. CheckMate227: phase 3 trial that showed that progression-free survival was significantly longer with combination therapy first with nivolumab than with chemotherapy among patients with NSCLC and high tumor mutational burden, irrespective of PD-L1 expression level.CrossRefPubMedGoogle Scholar
  12. 12.
    • Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. KEYNOTE-189: Phase 3 trial that showed that the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone in patients with patients with previously untreated metastatic NSCLC without EGFR or ALK mutations.CrossRefPubMedGoogle Scholar
  13. 13.
    Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–78.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non–small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124(2):271–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Hwang WL, Niemierko A, Hwang KL, et al. Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy. JAMA Oncol. 2017;  https://doi.org/10.1001/jamaoncol.2017.3808.
  17. 17.
    Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;  https://doi.org/10.1016/j.chest.2017.04.177.
  18. 18.
    Marrone KA, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100:242–51.CrossRefPubMedGoogle Scholar
  19. 19.••
    Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary. J Oncol Pract. 2018:JOP-18. First systematic review based guideline that offers a multidisciplinary recommendation of the management of immune-related adverse events, are based on.Google Scholar
  20. 20.
    Haanen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):119–42.CrossRefGoogle Scholar
  21. 21.
    Puzanov I, Diab A, Abdallah K, Bingham CO, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    • Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91.  https://doi.org/10.1093/annonc/mdv383. Comprehensive review of irAE associated with PD-1/PD-L1 blockade.PubMedGoogle Scholar
  23. 23.
    • Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. Comprehensive review of irAE associated with ICICrossRefPubMedGoogle Scholar
  24. 24.
    Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Winer A, Nicholas Bodor J, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018;10(Suppl 3):S480.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2016:annrheumdis-2016.Google Scholar
  28. 28.
    Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol. 2017;15(4):e80–1.CrossRefPubMedGoogle Scholar
  29. 29.
    Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581–92.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Roberts K, Culleton V, Lwin Z, O'Byrne K, Hughes BGM. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol. 2017;13(4):277–88.CrossRefPubMedGoogle Scholar
  32. 32.
    Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017;19(1):3.CrossRefPubMedGoogle Scholar
  34. 34.
    Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pem-brolizumab. JAMA Dermatol. 2016;152:45–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology. 2016;5(11):e1231292.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, Van Thienen JV, van Leerdam ME, van den Heuvel MM, Blank CU, van Dieren J, Haanen JB. Immune checkpoint inhibition-related colitis: correlation between ulcers and need for infliximab.Google Scholar
  38. 38.
    Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209.CrossRefPubMedGoogle Scholar
  39. 39.
    Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab+ ipilimumab. J Natl Cancer Inst. 2017;109(4):djw260.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Kim KW, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol. 2013;200(5):W468–74.CrossRefPubMedGoogle Scholar
  41. 41.
    Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82.CrossRefPubMedGoogle Scholar
  42. 42.
    Jain A, et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23(11):2023–8.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583–9.PubMedGoogle Scholar
  44. 44.
    Varricchi G, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation. 2017;136(21):1989–92.CrossRefPubMedGoogle Scholar
  45. 45.
    Kim KW, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs. 2013;31(4):1071–7.CrossRefGoogle Scholar
  46. 46.
    Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017;9:207–13.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050.CrossRefPubMedGoogle Scholar
  48. 48.
    Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–81.CrossRefPubMedGoogle Scholar
  49. 49.
    Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2016:annrheumdis-2016.Google Scholar
  50. 50.
    Nishino M, Sholl LM, Hatabu H, Ramaiya NH, Hodi FS. Anti–PD-1–related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373(3):288–90.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69(11):1751–63.CrossRefGoogle Scholar
  52. 52.
    Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22(6):627–30.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638–47.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8.CrossRefPubMedGoogle Scholar
  56. 56.
    Spain L, Walls G, Julve M, O’meara K, Schmid T, Kalaitzaki E, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017;28(2):377–85.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Beatriz Wills
    • 1
  • Julie R. Brahmer
    • 1
    • 2
  • Jarushka Naidoo
    • 1
    • 2
  1. 1.Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins BayviewJohns Hopkins UniversityBaltimoreUSA
  2. 2.Bloomberg-Kimmel Institute for Cancer ImmunotherapyJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations